Barts & The London NHS Trust

Quick facts

Marketed products

• Administration of paracetamol
• Combined Depo-Medrone and Lidocaine
• DMARD · Other
• Envarsus · Other
• Ergocalciferol (Vitamin D) · Endocrinology / Nutritional deficiency
  Ergocalciferol is a form of vitamin D that is converted in the body to its active metabolite, which regulates calcium and phosphate absorption and homeostasis.
• Paclitaxel protein bound · Oncology
  Paclitaxel protein-bound stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and halting cell division in cancer cells.

Phase 3 pipeline

• Darbepoetin alpha · Hematology/Oncology
  Darbepoetin alpha is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to stimulate red blood cell production.
• Migliol Placebo Oil
  Migliol is a medium-chain triglyceride oil used as a placebo or inert control vehicle in clinical trials.

Phase 2 pipeline

• Carboplatin AUC-10 · Oncology
  Alkylating agent that forms platinum-DNA adducts, inhibiting DNA replication and transcription.
• COVID-19 exposure · Infectious Diseases
  This drug aims to stimulate the immune system to fight COVID-19 infection.

Phase 1 pipeline

• Medical treatment alone
• Preset increase in frusemide dose

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Barts & The London NHS Trust portfolio CI brief
• Barts & The London NHS Trust pipeline updates RSS

Frequently asked questions about Barts & The London NHS Trust

Related

• Administration of paracetamol
• Combined Depo-Medrone and Lidocaine
• DMARD · Other
• Envarsus · Other
• Ergocalciferol (Vitamin D) · Endocrinology / Nutritional deficiency
• Sector hub: All tracked pharma companies